NYAS Conferences
New York Academy of Sciences
left end
Search
divider divider feedback right end
Annals of the New York Academy of Sciences Annals of the New York Academy of Sciences login

Main

Browse Volumes

Forthcoming Volumes

Annals PrePrints

Annals Extra

E-mail Alerts

Subscriptions & Orders

New Proposals

Author Guidelines

About Annals

Help

Get free Annals volume as a NYAS member: http://www.nyas.org/annalsreaderhw
Issue 1082 coverOligonucleotide Therapeutics: First Annual Meeting of the Oligonucleotide Therapeutics Society Volume 1082 published October 2006
Ann. N.Y. Acad. Sci. 1082: 77–90 (2006). doi: 10.1196/annals.1348.004
Copyright © 2006 by the New York Academy of Sciences
description | purchase volume purchase this volume

This Volume
Table of Contents
Description
This Article
Full Text
Full Text (PDF)
Services
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Citing Articles
Citing Articles via HighWire
Citing Articles via Google Scholar
Google Scholar
Articles by DORI, A.
Articles by SOREQ, H.
Search for Related Content
PubMed
PubMed Citation
Articles by DORI, A.
Articles by SOREQ, H.

Part II. Identifying and Validating Targets and Systems

Neuromuscular Therapeutics by RNA-Targeted Suppression of ACHE Gene Expression

AMIR DORIa AND HERMONA SOREQb

a Department of Neurology, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel 84105 b The Life Sciences Institute, The Hebrew University of Jerusalem, Jerusalem, Israel 91904

Key Words: anticholinergic treatment • antisense treatment • myasthenia gravis • neuromuscular junction • readthrough acetylcholinesterase

Address for correspondence: Hermona Soreq, The Life Sciences Institute, The Hebrew University of Jerusalem, Jerusalem, Israel 91904. Voice: +972-2-658-5109; fax: +972-2-652-0258.  e-mail: soreq{at}cc.huji.ac.il

RNA-targeted therapeutics offers inherent advantages over small molecule drugs wherever one out of several splice variant enzymes should be inhibited. Here, we report the use of Monarsen, a 20-mer acetylcholinesterase-targeted antisense agent with three 3'-2'o-methyl-protected nucleotides, for selectively attenuating the stress-induced accumulation of the normally rare, soluble "readthrough" acetylcholinesterase variant AChE-R. Acetylcholine hydrolysis by AChE-R may cause muscle fatigue and moreover, limit the cholinergic anti-inflammatory blockade, yielding inflammation-associated pathology. Specific AChE-R targeting by Monarsen was achieved in cultured cells, experimental animals, and patient volunteers. In rats with experimental autoimmune myasthenia gravis, oral delivery of Monarsen improved muscle action potential in a lower dose regimen (nanomolar versus micromolar), rapid and prolonged manner (up to 72 h versus 2–4 h) as compared with the currently used small molecule anticholinesterases. In central nervous system neurons of both rats and cynomolgus monkeys, systematic Monarsen treatment further suppressed the levels of the proinflammatory cytokines interleukin-1 (IL-1) and IL-6. Toxicology testing and ongoing clinical trials support the notion that Monarsen treatment would offer considerable advantages over conventional cholinesterase inhibitors with respect to dosing, specificity, side effects profile, and duration of efficacy, while raising some open questions regarding its detailed mechanism of action.




This article has been cited by other articles:


Home page
Ann. N. Y. Acad. Sci.Home page
J. D. SUSSMAN, Z. ARGOV, D. MCKEE, E. HAZUM, S. BRAWER, and H. SOREQ
Antisense Treatment for Myasthenia Gravis: Experience with Monarsen
Ann. N.Y. Acad. Sci., June 1, 2008; 1132(1): 283 - 290.
[Abstract] [Full Text] [PDF]



footerLeft footerRight